Details of the Drug Reposition

General Information of This Drug (ID: DMUZDFR)

Drug Name	WT2725 DMUZDFR

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 1	[1]
Haematological malignancy	DISCDP7W	2B33.Y	Phase 1	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01621542) Clinical Study of WT2725 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)